Short-term methotrexate plus cyclosporine for graft-versus-host disease prophylaxis after single-unit cord blood transplantation following reduced-intensity conditioning

DOI Web Site 32 References
  • Sugio Takeshi
    Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
  • Kato Koji
    Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Yoshida Shuro
    Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
  • Saito Noriyuki
    Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
  • Kawano Ichiro
    Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
  • Henzan Hideho
    Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
  • Miyamoto Toshihiro
    Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Akashi Koichi
    Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Eto Tetsuya
    Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan

Search this article

Description

<p> Background: Cord blood is an alternative donor source for patients without HLA-matched donors. Calcineurin inhibitors (CNIs) alone, as prophylaxis for graft-versus-host disease (GVHD) in cord blood transplantation (CBT) patients, reportedly increase the incidence of severe pre-engraftment immune reaction (PIR), leading to transplant-related mortality (TRM) with primary engraft failure and multiple organ dysfunctions. Therefore, additional immunosuppressive agents are needed. Reportedly, short-term methotrexate (sMTX) plus CNIs improved outcomes in patients receiving CBT with full-intensity conditioning (FIC) regimens; however, safety and efficacy of sMTX plus cyclosporine have not been assessed in patients receiving CBT with reduced-intensity conditioning (RIC) regimens. Methods: We retrospectively analyzed 43 patients who received single-unit CBT and were treated with sMTX plus cyclosporine (RIC group, 15; FIC group, 28). Results: Neutrophil engraftment rate was significantly lower in RIC group (53.3%) than in FIC group (78.6%, P=0.04). Cumulative incidence of TRM tended to be higher in the RIC group than in the FIC group (P=0.12); the leading cause of death in the RIC group was bacterial infections. Conclusions: sMTX plus cyclosporine does not seem feasible for treating patients receiving single-unit CBT following RIC. MTX dose optimization or alternative immunosuppressive agent application should be considered in such patients.</p>

Journal

References(32)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top